FKS1 mutation associated with decreased echinocandin susceptibility of *Aspergillus fumigatus* following anidulafungin exposure

Ana Pinto e Silva1,2*, Isabel Marcos Miranda3, Joana Branco1, Patricia Oliveira1, Isabel Faria-Ramos5, Raquel M. Silva4, Acácio Gonçalves Rodrigues1,2,5 & Sofia Costa-de-Oliveira1,2

Invasive aspergillosis (IA) is a potentially lethal infection that affects mostly immunocompromised patients caused by *Aspergillus fumigatus*. Echinocandins are a second-line therapy against IA, used as a salvage therapy as well as for empirical or prophylactic therapy. Although they cause lysis of growing hyphal tips, they are considered fungistatic against molds. In vivo echinocandins resistance is uncommon; however, its wide clinical use could shortly lead to the emergence of *A. fumigatus* resistance. The aims of the present work was to assess the development of reduced echinocandins susceptibility phenotype by a *A. fumigatus* strain and to unveil the molecular mechanism underlying such phenotype. We induced in vitro cross-resistance to echinocandins following exposure of *A. fumigatus* to anidulafungin. Stability of the resistant phenotype was confirmed after removal of anidulafungin pressure. The FKS1 gene was partially sequenced and a E671Q mutation was found. A computational approach suggests that it can play an important role in echinocandin resistance. Given the emerging importance of this mechanism for clinical resistance in pathogenic fungi, it would be prudent to be alert to the potential evolution of this resistant mechanism in *Aspergillus* spp infecting patients under echinocandins therapeutics.

Invasive aspergillosis (IA) is a potentially lethal infection afflicting mostly immunocompromised patients, the majority of cases caused by *Aspergillus fumigatus*. Early appropriate therapy is critical for the successful management. Echinocandins are clinically used in salvage therapy of IA as well as for empirical or prophylactic therapy1,2. Moreover, combination of voriconazole and anidulafungin (AFG) have been shown to be effective against azole-susceptible and azole-resistant *A. fumigatus* isolates3. The mechanism of action of echinocandins involves noncompetitive inhibition of (1,3)-β-D-glucan synthase, an essential enzyme involved in fungal cell wall synthesis. Echinocandins has been shown to cause lysis of growing hyphal tips but are considered fungistatic against moulds4. Elevated echinocandin Minimal Inhibitory Concentration (MIC) values for a variety of *Candida* clinical isolates were linked with genetic mutations in the hot spot regions of *FKS1* and *FKS2* genes5,6. Echinocandin resistance mechanisms are not yet clearly elucidated for *Aspergillus* spp. as in case of *Candida* spp.7.

The aim of the present work was to assess the development of reduced echinocandin susceptibility by an *A. fumigatus* clinical isolate exposed repeatedly in vitro to AFG and unveil the underlying molecular mechanisms.

---

1Division of Microbiology, Department of Pathology, Faculty of Medicine, University of Porto, Al. Hernâni Monteiro, 4200-319 Porto, Portugal. 2Center for Research in Health Technologies and Information Systems (CINTESIS), R. Dr. Plácido da Costa, 4200-450 Porto, Portugal. 3Department of Surgery and Physiology and Cardiovascular R&D Unit, Faculty of Medicine, University of Porto, Al. Hernâni Monteiro, 4200-319 Porto, Portugal. 4Department of Medical Sciences, iBIMED and IEETA, University of Aveiro, Aveiro, Portugal. 5Burn Unit, São João Hospital Center, Al. Hernâni Monteiro, 4200-319 Porto, Portugal. *email: anatpsilva@hotmail.com
Results and discussion

Dynamics of in vitro acquisition of resistance by *A. fumigatus* exposed to AFG is detailed in Table 1. After 30 days of exposure, resistance to AFG and cross-resistance to caspofungin (CAS) and micafungin (MFG) was developed. Exposure to AFG triggered macroscopic modification of morphology of *A. fumigatus* colonies, changing from the original green blue color to white (Fig. 1), becoming notably smaller. Microscopy showed absence of conidiation (data not shown). AFR0 and AFR1 showed the same macroscopic and microscopic phenotype. Similar changes have been reported in *A. fumigatus* exposed to antifungals during long periods. RAPD analysis exhibits high discriminatory power for analysis of *A. fumigatus* strains when using this set of primers. RAPD patterns obtained were 100% identical for the three strains (Fig. 2). A point mutation was found in AFR0 corresponding to replacement of glutamine by glutamate at position 671 of Fks1p (E671Q); similar mutation was found in AFR1. Since the resistant phenotype emerged abruptly, remaining stable following antifungal removal, it is highly plausible that this hot spot FKS1 mutation E671Q might be responsible for the reduced susceptibility of AFR0 and AFR1. A mutation in *A. fumigatus* FKS1 gene with potential to reduce echinocandin susceptibility is hereby described. Such mutation was never reported among *Candida* spp. An S678P amino acid change, equivalent to a mutation found in a resistant *Candida* isolate was described in a laboratory mutant of *A. fumigatus* and associated with resistance to CAS. A mutation resulting in a F675S amino acid change was found in a chronic pulmonary aspergillosis isolate from a patient in whom micafungin treatment failed. Point mutations in FKS1 genes are the main mechanism that is implicated in decreased echinocandin susceptibility, however, Arendrup and colleagues found no mutations in FKS1 gene in two clinical isolates of *A. fumigatus* with MIC > 32 µg/mL to CAS. Instead, an increased in FKS1 gene expression was observed. This mechanism may be implicated in tolerance to echinocandin therapy.

The E671Q mutation replaces an amino acid with a negatively charged side chain (glutamate) by an amino acid with a polar but uncharged side chain (glutamine). This position is conserved among several fungi (Fig. 3a). PROVEAN software considers an amino acid alteration at this position deleterious, suggesting that this region might have a relevant functional and/or structural role. According to the three-dimensional (3D) structure obtained, E671 establishes polar contacts with K668 and T677 amino acids. Substitution by a glutamine would disrupt two of the three contacts with T677, which could distort conformation of the protein (Fig. 3b), given the proximity to a transmembrane domain (amino acids 679–699 in *S. cerevisiae*). Therefore, E671 may be

| Induction day | MEC value (µg/mL) |
|--------------|-------------------|
|              | AFG | CAS | MFG |
| 0            | ≤0.015 | ≤0.015 | ≤0.015 |
| 5            | ≤0.015 | 0.06 | ≤0.015 |
| 10           | ≤0.015 | 0.125 | 0.03 |
| 15           | ≤0.015 | 0.125 | 0.06 |
| 20           | ≤0.015 | 0.125 | 0.125 |
| 25           | 0.03 | 0.25 | 0.125 |
| 30           | >8 | >8 | >8 |

Table 1. Echinocandin Minimal Effective Concentration (MEC) values anidulafungin (AFG), caspofungin (CAS) and micafungin (MFG) distribution during in vitro induction assay with AFG of an *A. fumigatus* clinical isolate.
necessary to maintain protein’s three-dimensional structure, supporting the assumption that such substitution could impair its function. Ultimately, two approaches might be taken: FKS1 gene deletion in resistant strain to determine whether reversion to the susceptible phenotype occurs and site-directed mutagenesis in wild-type strain to observe whether resistant phenotype arises. Nevertheless, other mechanisms might also be involved in the development of echinocandin resistance, such as remodeling of cell wall components namely chitin levels, production of reactive oxygen species, alteration of the composition of plasma membrane lipids or expression levels of echinocandin target enzyme genes\(^1\)\(^6\)\(^7\).

Our results suggest that modification of Fks1p in \textit{A. fumigatus} might confer echinocandins resistance. Given the emerging importance of clinical resistance among pathogenic fungi, it would be advisable to monitor the potential evolution of this mechanism in \textit{Aspergillus} isolates from patients under echinocandin therapy.

**Figure 2.** Random amplification of polymorphic DNA patterns, using primers (a) OPAX and (b) R108, (c) Primer 2 and (d) OPQ6, of \textit{Aspergillus fumigatus} strains (AF\(_S\), initial susceptible strain, AF\(_R\)\(_0\), resistant induced strain, and AF\(_R\)\(_1\), resistant strain after 30 days without antifungal) obtained during in vitro induction assay. AF\(_C\) represents a distinct \textit{A. fumigatus} clinical strain, with a different pattern. 100 bp DNA ladder.
Material and methods
A suspension of $5 \times 10^4$ conidia/mL of *A. fumigatus* (clinical bronchoalveolar lavage isolate) was prepared in YEPD broth (0.3% yeast extract, 1% peptone, 2% dextrose) supplemented with sub-Minimal Effective Concentration (sub-MEC) (0.06 µg/mL) of AFG (Pfizer, Inc.) and incubated overnight, at 35 °C, 180 rpm. One mL was daily transferred to fresh YEPD supplemented with AFG. In parallel, 1 mL aliquot of was frozen (− 80 °C) but also cultured on YEPD agar at 35 °C for 72 h, to confirm viability and purity of culture. AFG concentration was increased to double whenever fungal growth was prominent, reaching a final concentration of 8 µg/mL. In vitro induction was carried out up to 30 days. Every 5 days, MEC values of the 3 echinocandin were determined according to CLSI18. A MEC value ≥ 1 µg/mL was considered resistance19. In order to assess the stability of echinocandin MEC values increments, the induced strain was daily sub-cultured for an additional 30 days in the absence of antifungal and MEC values re-determined. The resistant pattern remained stable. At the end of the assay, three strains were characterized: the initial susceptible strain (AFS), the induced strain (AFR0) and the strain obtained following additional 30 days without antifungal exposure (AFR1).

Genotyping by random amplification of polymorphic DNA (RAPD) of strains AFS, AFR0, AFR1 using primers R108 (5′-GCT GGT GG-3′), OPAX (5′-AGT GCA CACC-3′), OPQ6 (5′-GAG CGC CTTG-3′) and Primer 2 (5′-GGT GAG TCG-3′) was performed11.

Following PCR with primers 5′-GCT GGT GG-3′, 5′-AGT GCA CACC-3′ OPAX, 5′-GAG CGC CTTG-3′ and Primer 2 (5′-GGT GAG TCG-3′) was performed11. A FKS1 hot spot regions (between 1,875 and 4,318 bp) of *FKS1* gene (GenBank accession no. AFU79728) from AFS, AFR0 and AFR1 strains were amplified and sequenced were sequenced by Sanger method. The sequences were analyzed using BLAST Sequence Analysis Tool of NCBI.

The three-dimensional model for the Fks1 protein structure was obtained by modeling using the I-TASSER online server as previously described20,21. Structures were visualized in PYMOL v1.1r1.

Received: 6 February 2020; Accepted: 3 June 2020
Published online: 20 July 2020
References

1. Dockrell, D. H. Salvage therapy for invasive aspergillosis. J. Antimicrob. Chemother. 61(Suppl 1), i41–i44. https://doi.org/10.1093/jac/dkm426 (2008).

2. Walsh, T. J. et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin. Infect. Dis. 46, 327–360. https://doi.org/10.1086/525258 (2008).

3. Seyedmousavi, S. et al. In vitro interaction of voriconazole and anidulafungin against triazole-resistant Aspergillus fumigatus. Antimicrob. Agents Chemother. 57, 796–803. https://doi.org/10.1128/AAC.00980-12 (2013).

4. Bowman, J. C. et al. The antifungal echinocandin caspofungin acutely kills growing cells of Aspergillus fumigatus in vitro. Antimicrob. Agents Chemother. 46, 3001–3012. https://doi.org/10.1128/AAC.46.9.3001-3012.2002 (2002).

5. Desnos-Ollivier, M. et al. Mutations in the fks1 gene in Candida albicans, C. tropicalis, and C. krusei correlate with elevated caspofungin MICs uncovered in AM3 medium using the method of the European Committee on Antibiotic Susceptibility Testing. Antimicrob. Agents Chemother. 52, 3092–3098. https://doi.org/10.1128/AAC.00888-08 (2008).

6. Costa-de-Oliveira, S. et al. FKS2 mutations associated with decreased echinocandin susceptibility of Candida glabrata following anidulafungin therapy. Antimicrob. Agents Chemother. 55, 1312–1314. https://doi.org/10.1128/AAC.00589-10 (2011).

7. Wiederhold, N. P. Antifungal resistance: current trends and future strategies to combat. Infect. Drug Resist. 10, 249–259. https://doi.org/10.2147/IDR.S124918 (2017).

8. Varanasi, N. L., Baskaran, I., Chandrasekar, P. H. & Manavathu, E. K. Novel effect of voriconazole on conidiation of Candida glabrata. J. Med. Microbiol. 53, 254–261. https://doi.org/10.1099/jmm.0.035298-0 (2004).

9. Faria-Ramos, I. et al. Development of cross-resistance by Aspergillus fumigatus to clinical azoles following exposure to prochorzaz, an agricultural azole. BMC Microbiol. 14, 155. https://doi.org/10.1186/1471-2180-14-155 (2014).

10. Jimenez-Ortigosa, C., Moore, C., Denning, D. W. & Perlin, D. S. Emergence of echinocandin resistance due to a point mutation in the fks1 gene of Aspergillus fumigatus in a patient with chronic pulmonary aspergillosis. Antimicrob. Agents Chemother. https://doi.org/10.1128/AAC.01277-17 (2017).

11. Menotti, J. et al. Epidemiological study of invasive pulmonary aspergillosis in a haematology unit by molecular typing of environmental and patient isolates of Aspergillus fumigatus. J. Hosp. Infect. 60, 61–68. https://doi.org/10.1016/j.jhin.2004.10.009 (2005).

12. Gardiner, R. E., Souteropoulos, P., Park, S. & Perlin, D. S. Characterization of Aspergillus fumigatus mutants with reduced susceptibility to caspofungin. Med. Mycol. 43(Suppl 1), S299–305. https://doi.org/10.1080/13693780400029023 (2005).

13. Rocha, E. M., Garcia-Effron, G., Park, S. & Perlin, D. S. A Ser678Pro substitution in Fks1p confers resistance to echinocandin drugs in Aspergillus fumigatus. Antimicrob. Agents Chemother. 54, 4174–4176. https://doi.org/10.1128/AAC.00917-07 (2010).

14. Arendrup, M. C. et al. Establishing in vitro–in vivo correlations for Aspergillus fumigatus: the challenge of azoles versus echinocandins. Antimicrob. Agents Chemother. 52, 3504–3511. https://doi.org/10.1128/AAC.00190-08 (2008).

15. Choi, Y., Sims, G. E., Murphy, S., Miller, J. R. & Chan, A. P. Predicting the functional effect of amino acid substitutions and indels. PLoS ONE 7, e46688. https://doi.org/10.1371/journal.pone.0046688 (2012).

16. Walker, L. A., Lee, K. K., Munro, C. A. & Gow, N. A. Caspofungin treatment of Aspergillus fumigatus mutants with reduced susceptibility to caspofungin results in ChsG-dependent upregulation of chitin synthesis and the formation of chitin-rich microcolonies. Antimicrob. Agents Chemother. 59, 5932–5941. https://doi.org/10.1128/AAC.00862-15 (2015).

17. Satish, S. et al. Stress-induced changes in the lipid microenvironment of beta-(1,3)-d-glucan synthase cause clinically important echinocandin resistance in Aspergillus fumigatus. mBio https://doi.org/10.1128/mBio.00779-19 (2019).

18. Institute, C. A. L. S. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Filamentous Fungi. Approved Standard 2nd edn (2008).

19. Espinel-Ingroff, A. et al. Wild-type MIC distributions and epidemiological cutoff values for amphotericin B and Aspergillus spp. for the CLSI broth microdilution method (M38–A2 document). Antimicrob. Agents Chemother. 55, 5130–5134. https://doi.org/10.1128/AAC.00868-11 (2011).

20. Yang, J. et al. The I-TASSER Suite: protein structure and function prediction. Nat. Methods 12, 7–8. https://doi.org/10.1038/nmth 3213 (2015).

21. Branco, J. et al. Impact of ERG3 mutations and expression of ergosterol genes controlled by UPC2 and NDT80 in Candida parapsilosis azole resistance. Clin. Microbiol. Infect. 23, 575e571–575e578. https://doi.org/10.1111/j.cmi.2017.02.002 (2017).

Acknowledgements

A.P.S and J.B. are supported by the Portuguese Technology and Science Foundation (FCT), respectively Grants SFRH/BPD/102831/2014 and SFRH/BD/135803/2018. This work was supported by Astellas and Grupo de Infeção e Sepsis from Centro Hospitalar São João (Clinical Mycology Research grant). The authors would like to thank Isabel Santos for her excellent technical assistance.

Author contributions

S.C.O., A.P.S. and I.M.M. design the study and conceived the experiments; A.P.S., J.B., P.O., I.F.R. performed the experiments; S.C.O., A.P.S., R.M.S. and A.G.R. analyzed the results; S.C.O. and A.P.S. wrote the manuscript. All authors revised the manuscript.

Competing interests

The authors declare no competing interests.

Additional information

Correspondence and requests for materials should be addressed to A.P.e.S.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
